Absci Corporation

ABSI · NASDAQ

ABSI is a clinical data story before it is a revenue story: ABS-201 could validate the AI-biologics platform, but Q1 2026 still shows tiny partner revenue, heavy R&D burn, and no product sales.

Follow Add to Watchlist Ask Question

NASDAQ ABSI Coverage Bootstrap Biotechnology AI Drug Discovery Clinical-Stage Biopharma

Latest ReportMay 13, 2026Absci (ABSI): the hair-regrowth data bet hiding inside an AI drug-discovery platformView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.